A series of biological barriers in a nanoparticle-formulated drug delivery process inevitably
result in the current low delivery efficiency, limited tumor penetration and insufficient cellular …

Poor drug delivery to solid tumors remains a great challenge for effective antitumor therapy.
Herein, multistage stimuli-responsive nanovectors based on hollow mesoporous silica …

The application of cytotoxic chemotherapeutics in cancer therapy has been largely restricted
by their lack of selectivity. Despite the existence of numerous targeted delivery systems, it is …

Nanomedicine to overcome both systemic and tumor tissue barriers ideally should have a
transformable size and surface, maintaining a certain size and negative surface charge for …

It is generally known that, for nanoparticles in cancer therapy, sufficient tumor penetration
needs a minor particle size, while long in vivo circulation time needs a larger particle size. It …

Despite the significant advancements in the development of a wide-variety of nanocarriers-
based delivery systems for cancer therapy, several predominant issues remain unaddressed …

Two novel stimuli-responsive drug delivery systems (DDSs) were successfully created from
bovine serum albumin-or myoglobin-gated upconversion nanoparticle-embedded …

The currently low delivery efficiency and limited tumor penetration of nanoparticles remain
two major challenges of cancer nanomedicine. Here, we report a class of pH-responsive …

The several biological barriers that nanoparticles might encounter when administered to a
patient constitute the major bottleneck of nanoparticle-mediated tumor drug delivery …

Poor tumor accumulation remains a serious challenge for nanomedicines to achieve ideal
antitumor outcomes. The different size preferences for systematic circulation, tumor retention …